Depression in Alzheimer’s disease: Is the combination of citalopram and rivastigmine better than rivastigmine alone? A longitudinal clinical trial
نویسندگان
چکیده
منابع مشابه
Case Report Rivastigmine in Wernicke-korsakoff’s Syndrome: Five Patients with Rivastigmine Showed No More Improvement than Five Patients without Rivastigmine
Aims: To evaluate whether rivastigmine, an achetylcholinesterase inhibitor (AChEl), may be effective in restoring memory in Wernicke-Korsakoff’s syndrome (WKS). Methods: Five patients treated with rivastigmine for a period of 6 months were compared with five matched control patients, who received 6 months’ conventional treatment, but without rivastigmine. Memory tests were administered at basel...
متن کاملRivastigmine in Wernicke-Korsakoff's syndrome: five patients with rivastigmine showed no more improvement than five patients without rivastigmine.
AIMS To evaluate whether rivastigmine, an achetylcholinesterase inhibitor (AChEl), may be effective in restoring memory in Wernicke-Korsakoff's syndrome (WKS). METHODS Five patients treated with rivastigmine for a period of 6 months were compared with five matched control patients, who received 6 months' conventional treatment, but without rivastigmine. Memory tests were administered at basel...
متن کاملIs Rivastigmine Effective in the Treatment of Alzheimer’s Disease?
OBJECTIVE: The objective of this selective EBM review is to determine whether or not rivastigmine is effective for the treatment of Alzheimer’s Disease. STUDY DESIGN: Review of two trials in the English language published in 2007 and 2010, and an open-label, singlearm, multi-center study from 2008. DATA SOURCES: Randomized, double-blind, placebo-controlled trials comparing rivastigmine to a vis...
متن کاملBrain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
In-vivo metabolic measures with positron emission tomography using (18)F-fluorodeoxyglucose (FDG-PET) have demonstrated hypometabolism in temporal, frontal, and hippocampal areas during the early stages of Alzheimer's disease (AD). Progression of the dementia in AD involves compromised cholinergic functioning. Cholinesterase inhibitors have demonstrated efficacy in improving cognition and behav...
متن کاملRivastigmine: in Parkinson's disease dementia.
Rivastigmine is a carbamate-type dual inhibitor of brain acetyl- and butyrylcholinesterases that has been evaluated in the symptomatic treatment of patients with mild to moderate dementia associated with idiopathic Parkinson's disease. Oral rivastigmine 3-12 mg/day for 24 weeks was significantly more effective than placebo in ameliorating cognitive and functional decline, including attentional ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Alzheimer's & Dementia
سال: 2020
ISSN: 1552-5260,1552-5279
DOI: 10.1002/alz.047102